The objective of this proposal is to establish and maintain the NCORP (National Community Oncology Research Program) for the NRG Oncology research base. The NRG NCORP is the result of aligning the legacy CCOPs (Community Clinical Oncology Programs) from three NCI Cancer Cooperative Groups: NSABP, RTOG and GOG. These groups together have over almost 100 years of combined experience serving as CCOP Research Bases. NRG NCORP, comprised of a multi-disciplinary team of investigators and patient advocates, is poised to carry out the objectives of: 1) designing and conducting cancer prevention, control and screening clinical trials; 2) designing and embedding patient reported outcomes in both primary NCOPR trials as well as NRG therapeutic trials 3) designing and conducting cancer care delivery research; 4) enhancing community access to treatment and imaging trials conducted under the National Clinical Trials Network (NCTN) and 5) conducting primary intervention trials and integrating health disparity research questions into cancer care delivery research and treatment trials. To allow NRG NCORP to meet these goals, the group will: participate fully in NRG Oncology leadership and will determine the scientific direction and prioritization of the NRG NCORP activities and resources and oversee the translational research, clinical trial activities, and correlative studies related to the aims of NRG NCORP. With the NRG Statistical and Data Management Center (SDMC), this team will provide efficient, methodologically up-to-date trial design with a focus on NCORP specific needs such as patient-reported repeated longitudinal assessments and cluster-randomized designs. NRG NCORP will provide study monitoring, reporting, and analysis; build an infrastructure to support our cancer care delivery research agenda; provide comprehensive data management quality control and quality assurance programs to ensure high data integrity and timely data for analysis; leverage cutting edge information technology emphasizing security, timeliness, and efficiency of data collection and management; providing RT credentialing and quality assurance; and provide education and training for institutional Clinical Research Associates, Study Chairs, local Principal Investigators and others involved in the NRG NCORP research agenda. Further, to accomplish these aims NRG NCORP will engage fully with NCI-designated NCORP community physicians and patient advocates as well as the NCI and other NCI-sponsored entities (cooperative groups, cancer centers, SPOREs) to collaborate across the NCTN to improve cancer prevention and control, cancer care and outcomes, and quality of life for patients affected by cancer.

Public Health Relevance

NRG Oncology NCORP research will significantly impact cancer prevention, screening, control and care delivery, and bring state-of-the-art treatment trials to community centers where most cancer treatments are delivered. NRG NCORP will conduct high impact studies for patients with many types of solid tumors with a particular unique focus in both women's health and cancer control issues related to radiation therapy. To accomplish these aims NRG NCORP will engage fully with community physicians and patient advocates as well as the NCI and NCI- designated cancer centers to collaborate to improve cancer prevention and control, cancer care and outcomes, and quality of life for patients affected by cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
2UG1CA189867-06
Application #
9771790
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Russo, Sandra
Project Start
2014-08-01
Project End
2025-07-31
Budget Start
2019-08-20
Budget End
2020-07-31
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Nrg Oncology Foundation, Inc.
Department
Type
DUNS #
078695317
City
Philadelphia
State
PA
Country
United States
Zip Code
19103
Ahmed, Amina; Deng, Wei; Tew, William et al. (2018) Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study. Gynecol Oncol 150:300-305
Coen, John J; Zhang, Peixin; Saylor, Philip J et al. (2018) Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. J Clin Oncol :JCO1800537
Ingle, James N; Kalari, Krishna R; Wickerham, Donald Lawrence et al. (2018) Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab. Pharmacogenet Genomics 28:147-152
Ali, Arif N; Zhang, Peixin; Yung, W K Alfred et al. (2018) NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol 137:39-47
Dignam, James J; Hamstra, Daniel A; Lepor, Herbert et al. (2018) Time Interval to Biochemical Failure as a Surrogate End Point in Locally Advanced Prostate Cancer: Analysis of Randomized Trial NRG/RTOG 9202. J Clin Oncol :JCO1800154
Videtic, Gregory M; Paulus, Rebecca; Singh, Anurag K et al. (2018) Long term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase II study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys :
Mamounas, Eleftherios P; Tang, Gong; Paik, Soonmyung et al. (2018) 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. Breast Cancer Res Treat 168:69-77
Lawrence, Yaacov R; Moughan, Jennifer; Magliocco, Anthony M et al. (2018) Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704. Cancer 124:491-498
Rogers, Leland; Zhang, Peixin; Vogelbaum, Michael A et al. (2018) Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg 129:35-47
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121

Showing the most recent 10 out of 180 publications